This company has been marked as potentially delisted and may not be actively trading. NASDAQ:DRNA Dicerna Pharmaceuticals (DRNA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Dicerna Pharmaceuticals Stock (NASDAQ:DRNA) 30 days 90 days 365 days Advanced Chart Get DRNA alerts:Sign Up Key Stats Today's Range$38.22▼$38.2250-Day Range$37.81▼$38.2552-Week Range$19.06▼$40.14VolumeN/AAverage Volume1.34 million shsMarket Capitalization$2.99 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. Read More Receive DRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dicerna Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DRNA Stock News HeadlinesArrowhead Pharmaceuticals (NASDAQ: ARWR)May 25, 2023 | fool.com'Mad Money' Lightning Round: I'm Staying Away From Five BelowFebruary 16, 2023 | thestreet.comGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an epic bull rally in gold. JP Morgan and Goldman Sachs have a price target of $4,000. My research tells me gold could surpass $5,000 in the coming months. Folks using a very specific gold strategy since the 80s could have made more than 60 TIMES their money. Today, you can take advantage of a similar setup for around $10July 6 at 2:00 AM | Stansberry Research (Ad)BiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News SummaryFebruary 7, 2023 | benzinga.comMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028January 26, 2023 | marketwatch.comWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business GrowthJanuary 18, 2023 | finance.yahoo.comDRNA Jan 2022 22.500 callJanuary 14, 2022 | ca.finance.yahoo.comDRNA Jul 2022 40.000 call(CONTRJanuary 14, 2022 | ca.finance.yahoo.comSee More Headlines DRNA Stock Analysis - Frequently Asked Questions How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.19. The biopharmaceutical company had revenue of $62.95 million for the quarter, compared to analysts' expectations of $58.83 million. Dicerna Pharmaceuticals had a negative trailing twelve-month return on equity of 103.08% and a negative net margin of 64.53%. Read the conference call transcript. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Marvell Technology (MRVL), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and PayPal (PYPL). Company Calendar Last Earnings11/09/2021Today7/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:DRNA CIK1399529 Webwww.dicerna.com Phone(617) 621-8097Fax617-612-6298Employees302Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$112.75 million Net Margins-64.53% Pretax Margin-63.82% Return on Equity-103.08% Return on Assets-16.58% Debt Debt-to-Equity RatioN/A Current Ratio2.46 Quick Ratio2.46 Sales & Book Value Annual Sales$164.31 million Price / Sales18.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.84 per share Price / Book20.77Miscellaneous Outstanding Shares78,129,000Free Float70,160,000Market Cap$2.99 billion OptionableOptionable Beta0.80 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:DRNA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored140% Yields From Stocks Like Tesla? Here's How (July 4th Special)Imagine getting a 140% dividend from your investments. Even better? It works with big names like Tesla, ...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dicerna Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.